Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

Data Compilation
#PharmaFlow

Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals

Stock Recap
#PipelineProspector

Rivastigmine Tartrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 18 USDMF, 12 CEP/COS, 15 EU WC, 20 KDMF, 5 NDC API, 25 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

120 FDF Dossiers, 46 FDA Orange Book, 40 Europe, 29 Canada, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 10 DKSH, 3 Faran Shimi Pharmaceutical, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 10 Corel Pharma Chem, 2 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 15 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 17 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

48 Coating Systems & Additives, 39 Fillers, Diluents & Binders, 20 Thickeners and Stabilizers, 20 Controlled & Modified Release, 15 Lubricants & Glidants, 15 Direct Compression, 12 Granulation, 11 Film Formers & Plasticizers, 9 Empty Capsules, 9 Taste Masking, 8 Co-Processed Excipients, 8 Disintegrants & Superdisintegrants, 6 Chewable & Orodispersible Aids, 5 Coloring Agents, 5 Emulsifying Agents, 5 Topical, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 API Stability Enhancers, 3 Solubilizers, 1 Parenteral, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

7 News #PharmaBuzz

7 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 Regulatory FDF Prices

12 Regulatory FDF Prices

MARKET PLACE

3 APIs

3 APIs

PATENTS & EXCLUSIVITIES

11 Health Canada Patents

11 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
25/04/2025	Dr. Reddy\'s Laboratories	India	DR REDDYS LABORATORIES LTD	17249	RIVASTIGMINE HYDROGEN TARTRATE	2004-03-19	Active	II	N/A
25/04/2025	Dr. Reddy\'s Laboratories	India	DR REDDYS LABORATORIES LTD	21781	RIVASTIGMINE HYDROGEN TARTRATE (PROCESS II )	2008-07-08	Active	II	N/A

Rivastigmine Tartrate

Rivastigmine Tartrate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

50 API Suppliers

18 USDMF

12 CEP/COS

15 EU WC

20 KDMF

5 NDC API

25 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

6 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

120 FDF Dossiers

46 FDA Orange Book

40 Europe

29 Canada

5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

10 DKSH

3 Faran Shimi Pharmaceutical

3 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

4 ACG Worldwide

5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 BASF

10 Corel Pharma Chem

2 DFE Pharma

1 Finar

6 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

2 Ingredion Pharma Solutions

15 Kerry

3 Kima Chemical

6 Lonza Capsugel

10 Microlex e.U

1 Novo Excipients

1 Pharmatrans-Sanaq

3 Pluviaendo

2 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

17 Roquette

8 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Sigachi Industries

2 Silverline Chemicals

2 The Dow Chemical Company

1 Valens Pharmachem

2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

48 Coating Systems & Additives

39 Fillers, Diluents & Binders

20 Thickeners and Stabilizers

20 Controlled & Modified Release

15 Lubricants & Glidants

15 Direct Compression

12 Granulation

11 Film Formers & Plasticizers

9 Empty Capsules

9 Taste Masking

8 Co-Processed Excipients

8 Disintegrants & Superdisintegrants

6 Chewable & Orodispersible Aids

5 Coloring Agents

5 Emulsifying Agents

5 Topical

CAPSULE;ORAL - EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons